LH Stock Recent News

Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.